HOT-TAKE

A collection of 46 posts

Paid-members only

Illumina

HOT TAKE: Illumina sees signals that the sequencing market is recovering

Paid-members only

Regulations

HOT TAKE: With lawsuits percolating in the background, CAP, Congress and others start working on VALID 2.0

Paid-members only

FDA

Just when you thought you might be safe, FDA sticks its nose into MRD testing (again)

Paid-members only

HOT-TAKE

A four legged adventure into the world of cancer vaccines

Paid-members only

HOT-TAKE

A round-up of everything that happened this year (tech wise) at #ASHG

Paid-members only

HOT-TAKE

Will PacBio's new chemistry SPRQ renewed interest in clinical long-reads?

Paid-members only

Exomes

Element Bioscience makes a big bet on rapid exome sequencing

Paid-members only

Genomic Sequencing

After 13 years, Illumina's 'little sequencer that could' has been replaced by a bigger, faster sibling

Paid-members only

Start-Upomics

Let's Get Checked buys TruePill to take on end-to-end at home healthcare

Paid-members only

Start-Upomics

Guardant Co-CEO's million dollar bet roils patients, employees and anyone with two functioning brain cells

Paid-members only

Genetic Screening

Australia just banned the life insurance industry from using genetic testing; America should too

Paid-members only

CRISPR

CRISPR isn't the only relevant genome engineering technique, can we talk about the others too, please?

Paid-members only

Start-Upomics

Illumina recently courted investors with a presentation on how their new product R&D pipeline is going to resurrect the Illumina stock price

Paid-members only

Start-Upomics

Nabsys is back, baby!

Paid-members only

Genomic Sequencing

Oxford Nanopore says that the short-read vs long-read conversation is pointless because they can do both

Paid-members only

Start-Upomics

The 23andMe board tells Anne Wojcicki to do better in her attempt to take 23andMe private after a rocky 3 years as a public company

Paid-members only

Protein Sequencing

There are a lot of companies working on protein sequencing, so who is in the lead?

Paid-members only

Start-Upomics

Everything that happened this week in short-reads

Paid-members only

Omics

One of the most underappreciated techniques in Omics is Hi-C. That needs to change

Paid-members only

Start-Upomics

The Grail/Illumina Class-Action lawsuit gets a juicy update

Paid-members only

Start-Upomics

Tempus' good very bad week included a $410m IPO, a lawsuit and a ~$20 swing in their post-IPO stock price

Paid-members only

High-Throughput Sequencing

If you thought the sequencing wars were hot already, have you considered what a $10 genome might do to them?

Paid-members only

Start-Upomics

Who's prioritizing bringing the next generation of sequencing technology to the clinic? The answer might surprise you.

Paid-members only

Start-Upomics

Grail might have been too bold a choice for a company name

Paid-members only

High-Throughput Sequencing

Another summer of sequencing is upon us. Whose sparkle will beguile the hearts of suitors and dazzle the eyes of onlookers?